Lazo Antonio, de la Torre-Luque Alejandro, Arregui Gregorio, Rivas Daniel, Serradilla Ana, Gómez Joaquin, Jurado Francisca, Núñez María Isabel, López Escarlata
Department of Radiation Oncology, San Cecilio Clinical University Hospital, 18016 Granada, Spain.
Department of Legal Medicine, Psychiatry and Pathology, CIBERSAM, Complutense University of Madrid, 28040 Madrid, Spain.
Biology (Basel). 2022 Mar 11;11(3):435. doi: 10.3390/biology11030435.
This retrospective study aimed to provide some clinical outcomes regarding effectiveness, toxicity, and quality of life in PCa patients treated with dose-escalated moderately hypofractionated radiation therapy (HFRT). Patients received HFRT to a total dose of 66 Gy in 22 fractions (3 Gy/fraction) delivered via volume modulated arc therapy (VMAT) in 2011-2016. Treatment effectiveness was measured by the biochemical failure-free survival rate. Toxicity was assessed according to the criteria of the Radiation Therapy Oncology Group (RTOG) and quality of life according to the criteria of the European Organization for Research and Treatment of Cancer (EORTC). In this regard, quality of life (QoL) was measured longitudinally, at a median of 2 and 5 years after RT. Enrolled patients had low-risk (40.2%), intermediate-risk (47.5%), and high-risk (12.3%) PCa. Median follow-up was 75 months. The biochemical failure-free survival rate was 94.2%. The incidence of acute grade 2 or higher gastrointestinal (GI) and genitourinary (GU) toxicity was 9.84% and 28.69%, respectively. The incidence rate of late grade 2 or higher GI and GU toxicity was 1.64% and 4.10%, respectively. Expanded Prostate Cancer Index Composite (EPIC) scores showed that the majority of patients maintained their QoL. HFRT to 66 Gy with VMAT was associated with adequate biochemical control, low toxicity and good reported GU and GI quality of life.
这项回顾性研究旨在提供一些关于接受剂量递增的中度低分割放射治疗（HFRT）的前列腺癌（PCa）患者的有效性、毒性和生活质量的临床结果。2011年至2016年期间，患者通过容积调强弧形放疗（VMAT）接受了总剂量为66 Gy、分22次（每次3 Gy）的HFRT。治疗有效性通过无生化失败生存率来衡量。毒性根据放射治疗肿瘤学组（RTOG）的标准进行评估，生活质量根据欧洲癌症研究与治疗组织（EORTC）的标准进行评估。在这方面，生活质量（QoL）在放疗后中位2年和5年时进行纵向测量。入组患者患有低危（40.2%）、中危（47.5%）和高危（12.3%）前列腺癌。中位随访时间为75个月。无生化失败生存率为94.2%。2级或更高等级的急性胃肠道（GI）和泌尿生殖系统（GU）毒性发生率分别为9.84%和28.69%。2级或更高等级的晚期GI和GU毒性发生率分别为1.64%和4.10%。扩展前列腺癌指数综合（EPIC）评分显示，大多数患者维持了他们的生活质量。采用VMAT进行66 Gy的HFRT与充分的生化控制、低毒性以及良好的报告的GU和GI生活质量相关。
